## Pilot Study 3 of Outpatient Control-to-Range: Safety and Efficacy with Day-and-Night In-Home Use Visit 6- 24-Hour Closed-Loop Debrief Visit

dentifying Information					
PtID	1. Patient ID: CTR3				
Namecode	2. Initials:				
Visit Information					
VisitDt	1. Visit Date: / / mm/dd/yy				
InvID	2. Study ID of Investigator:				
QuestionnaireCompleted	Did the subject and care giver complete the DiAs Questionniare and Clarke Hypoglycemia Awareness Questionnaire?				
adoute man o o mprotos					
	☐Yes ☐No (Please comment below)				
QuestionnaireCompletedDs	Comment:				
StudySuppliesReturned	Were all system study supplies returned?				
	□Yes □No ( <i>Please comment below)</i>				
StudySuppliesReturnedDs	Comment:				

<u></u>	

## **Adverse Events Since Last Contact**

SevHypo	Did the subject have a severe hypoglycemic episode requiring assistance of another person to administer carbohydrate, glucagon or other resuscitative actions not already reported?					
	□Yes □No (If Yes, complete a Severe Hypo Event Form)					
	Did the subject have a DKA not already reported?  □Yes □No (If Yes, complete a DKA Event Form)					
SevHyper	DKA is defir	DKA is defined as follows by the DCCT, and has all of the following:				
	•	Symptoms such as polyuria, polydipsia, nausea, or vomiting;				
	•	Serum ketones or large/moderate urine ketones;				
	<ul> <li>Either arterial blood pH &lt;7.30 or venous pH &lt;7.24 or serum bicarbonate &lt;15; and</li> </ul>					
	•	Treatment provided in a health care facility				
		Have any adverse events or any unexpected medical occurrence that is study or device related occurred that has not already been reported?				
	□Yes □No (If Yes, complete an Adverse Event Form)					
AdverseEvent						

If subject had severe hypoglycemia or DKA, the subject is no longer eligible to continue in the study. Please complete a Final Status form.

If there have been any changes made in insulin therapy, please submit the changes in the Insulin Therapy Form.